Exacerbation of recalcitrant cutaneous sarcoidosis with adalimumab - a paradoxical effect? A case report

The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequently as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of adalimumab in cutaneous sarcoidosis, although all of them...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Guida, Sousa, Lourdes Emerenciano, João, Alexandre Miguel Bruno Lopes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2013
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3875971/
https://www.ncbi.nlm.nih.gov/pubmed/24346872
http://dx.doi.org/10.1590/abd1806-4841.20132487
Descripción
Sumario:The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequently as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of adalimumab in cutaneous sarcoidosis, although all of them show good results. More recently, sarcoidosis onsets have been reported with various TNF-alpha inhibitors. The current case is, to our knowledge, the first to describe the exacerbation of cutaneous lesions of sarcoidosis treated with adalimumab.

Ejemplares similares